Key findings include the following: Chimeric antigen receptor T cell (CAR-T) therapy trials have revolutionized the treatment of relapsed B cell acute lymphoblastic leukemia (B-ALL); however, these clinical trials might not be equally accessible to all patients.  External provider implicit bias may influence referral of patients and partnerships between CAR-T centers and external hospital sites are needed to help address these disparities.